[A19-24] Abemaciclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A18-72
Last updated 02.05.2019
Commission awarded on 11.03.2019 by the Federal Joint Committee (G-BA).
Initial endocrine therapy in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer
Still indication of lesser benefit in comparison with appropriate comparator therapy
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.